Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD17 PET-adapted first-line treatment optimization for intermediate-stage Hodgkin lymphoma
NL-OMON47350Phase 3Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine and 3 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Progression-free survival. Started Mar 2013; status: active, not recruiting.
02
Drugs
bleomycinetoposidedoxorubicincyclophosphamidevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON47350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47350.